

DAFTAR PUSTAKA

1. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. *Nat Rev Dis Primers*. 2016;2:16061.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin*. 2016;66(1):7-30.
3. Atallah GA, Abd Aziz NH, Teik CK, Shafiee MN, Kampan NC. New Predictive Biomarkers for Ovarian Cancer. *Diagnostics (Basel)*. 2021;11(3).
4. Ri K. Riset kesehatan dasar. Jakarta: Badan Penelitian dan pengembangan Kesehatan Kementrian Kesehatan RI. 2013.
5. Doubeni CA, Doubeni AR, Myers AE. Diagnosis and Management of Ovarian Cancer. *Am Fam Physician*. 2016;93(11):937-44.
6. Savant SS, Sriramkumar S, O'Hagan HM. The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer. *Cancers (Basel)*. 2018;10(8).
7. Kampan NC, Madondo MT, Reynolds J, Hallo J, McNally OM, Jobling TW, et al. Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer. *Sci Rep*. 2020;10(1):2213.
8. Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. *Am J Epidemiol*. 2003;158(7):629-38.
9. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol*. 2014;6(10):a016295.
10. Mohammadian M, Ghafari M, Khosravi B, Salehiniya H, Aryaie M, Bakeshei FA, et al. Variations in the incidence and mortality of ovarian cancer and their relationship with the human development index in European Countries in 2012. *Biomedical Research and Therapy*. 2017;4(08):1541-57.
11. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. *Int J Womens Health*. 2019;11:287-99.
12. Mogensen JB, Kjær SK, Mellemkjær L, Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study. *Gynecol Oncol*. 2016;143(1):87-92.
13. Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet*. 2018;143 Suppl 2:59-78.
14. Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. *J Oncol*. 2011;2011:475983.
15. Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S, et al. The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. *Front Oncol*. 2017;7:24.
16. Maiuri AR, O'Hagan HM. Chapter Three - Interplay Between Inflammation and Epigenetic Changes in Cancer. In: Pruitt K, editor. *Progress in Molecular Biology and Translational Science*. 144: Academic Press; 2016. p. 69-117.
17. Ingerslev K, Hogdall E, Schnack TH, Skovrider-Ruminski W, Hogdall C, Blaakaer J. The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis. *Infect Agent Cancer*. 2017;12:25.

18. Takaya R, Fukaya T, Sasano H, Suzuki T, Tamura M, Yajima A. Macrophages in normal cycling human ovaries; immunohistochemical localization and characterization. *Hum Reprod.* 1997;12(7):1508-12.
19. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol.* 2013;14(10):1014-22.
20. Burghaus S, Häberle L, Schrauder MG, Heusinger K, Thiel FC, Hein A, et al. Endometriosis as a risk factor for ovarian or endometrial cancer - results of a hospital-based case-control study. *BMC Cancer.* 2015;15:751.
21. Gunderson CC, Ding K, Dvorak J, Moore KN, McMeekin DS, Benbrook DM. The pro-inflammatory effect of obesity on high grade serous ovarian cancer. *Gynecol Oncol.* 2016;143(1):40-5.
22. Muscat JE, Huncharek MS. Perineal talc use and ovarian cancer: a critical review. *Eur J Cancer Prev.* 2008;17(2):139-46.
23. Integrated genomic analyses of ovarian carcinoma. *Nature.* 2011;474(7353):609-15.
24. Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, et al. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. *Mol Cancer Ther.* 2006;5(2):382-90.
25. Gupta M, Babic A, Beck AH, Terry K. TNF- α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis? *Hum Pathol.* 2016;54:82-91.
26. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. *Cancer Res.* 2007;67(2):585-92.
27. Nilsson MB, Langlely RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. *Cancer Res.* 2005;65(23):10794-800.
28. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. *J Leukoc Biol.* 2006;80(2):227-36.
29. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. *J Clin Invest.* 1999;103(9):1237-41.
30. Wang Y, Ma J, Shen H, Wang C, Sun Y, Howell SB, et al. Reactive oxygen species promote ovarian cancer progression via the HIF-1 α /LOX/E-cadherin pathway. *Oncol Rep.* 2014;32(5):2150-8.
31. Yung MM, Tang HW, Cai PC, Leung TH, Ngu SF, Chan KK, et al. GRO- α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NF κ B signaling cascade. *Theranostics.* 2018;8(5):1270-85.
32. Chen S-U, Chou C-H, Lee H, Ho C-H, Lin C-W, Yang Y-S. Lysophosphatidic Acid Up-Regulates Expression of Interleukin-8 and -6 in Granulosa-Lutein Cells through Its Receptors and Nuclear Factor- κ B Dependent Pathways: Implications for Angiogenesis of Corpus Luteum and Ovarian Hyperstimulation Syndrome. *The Journal of Clinical Endocrinology & Metabolism.* 2008;93(3):935-43.
33. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, et al. Lysophosphatidic acid induction of vascular endothelial growth factor

- expression in human ovarian cancer cells. *J Natl Cancer Inst.* 2001;93(10):762-8.
34. Yu X, Zhang Y, Chen H. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. *BMC Cancer.* 2016;16(1):846.
 35. Cohen S, Mehrabi S, Yao X, Millingen S, Aikhionbare FO. Reactive Oxygen Species and Serous Epithelial Ovarian Adenocarcinoma. *Cancer Res J (N Y N Y).* 2016;4(6):106-14.
 36. Kim B, Jung JW, Jung J, Han Y, Suh DH, Kim HS, et al. PGC1 α induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells. *Oncotarget.* 2017;8(36):60299-311.
 37. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. *Cancer Lett.* 2010;295(1):110-23.
 38. Chou CH, Wei LH, Kuo ML, Huang YJ, Lai KP, Chen CA, et al. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. *Carcinogenesis.* 2005;26(1):45-52.
 39. Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. *Cancer Manag Res.* 2018;10:6685-93.
 40. Szulc-Kielbik I, Kielbik M, Nowak M, Klink M. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. *Biochim Biophys Acta Rev Cancer.* 2021;1876(2):188639.
 41. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. *Gynecol Oncol.* 1997;66(1):27-30.
 42. Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, et al. Plasma immune analytes in patients with epithelial ovarian cancer. *Cytokine.* 2015;73(1):108-13.
 43. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. *J Biol Chem.* 2004;279(10):9190-8.
 44. Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. *Cancer Lett.* 2007;247(1):130-6.
 45. Putri K, Tambunan B, Sandhika W. Diagnostic Value Of Ca-125 In Patients With Epithelial Ovarian Cancer At The Dr. Soetomo General Hospital Surabaya In 2016. *Indonesian Journal Of Clinical Pathology And Medical Laboratory.* 2019;25:145.
 46. Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. *Clin Biochem.* 2011;44(10-11):884-8.
 47. Vorgias G, Iavazzo C, Savvopoulos P, Myriokefalitaki E, Katsoulis M, Kalinoglou N, et al. Can the preoperative Ca-125 level predict optimal

- cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. *Gynecol Oncol.* 2009;112(1):11-5.
48. Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, et al. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. *J Surg Oncol.* 2010;101(1):13-7.
 49. Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? *Gynecol Oncol.* 2013;128(3):579-83.
 50. James NE, Chichester C, Ribeiro JR. Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer. *Front Oncol.* 2018;8:124.
 51. Wang H, Zhu L, Gao J, Hu Z, Lin B. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells. *Oncol Rep.* 2015;33(1):403-12.
 52. Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. *Biochem Biophys Res Commun.* 2012;419(2):274-80.
 53. Ribeiro JR, Gaudet HM, Khan M, Schorl C, James NE, Oliver MT, et al. Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracellular Matrix. *Front Oncol.* 2017;7:332.
 54. Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. *Am J Obstet Gynecol.* 2011;205(4):358.e1-6.
 55. Chen X, Zhou H, Chen R, He J, Wang Y, Huang L, et al. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. *Clin Chim Acta.* 2015;440:57-63.
 56. Shen Y, Li L. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer. *Tumour Biol.* 2016;37(11):14765-72.
 57. Feng LY, Liao SB, Li L. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study. *J Ovarian Res.* 2020;13(1):17.
 58. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. *Gynecol Oncol.* 2013;129(1):258-64.
 59. Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, et al. Ovarian cancer in younger vs older women: a population-based analysis. *Br J Cancer.* 2006;95(10):1314-20.
 60. Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. *PLoS One.* 2018;13(10):e0205000.
 61. Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? *Obstet Gynecol.* 2003;102(1):156-61.
 62. Chan JK, Loizzi V, Magistris A, Lin F, Rutgers J, Osann K, et al. Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer. *Clin Cancer Res.* 2004;10(24):8538-43.

63. Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. *Cancer*. 1996;77(6):1131-6.
64. Poole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y, et al. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. *Cancer Epidemiol Biomarkers Prev*. 2013;22(3):429-37.
65. Ørskov M, Iachina M, Guldberg R, Mogensen O, Mertz Nørgård B. Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study. *BMJ Open*. 2016;6(4):e010123.
66. Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. *Eur J Cancer*. 2007;43(4):690-709.
67. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. *Am J Epidemiol*. 1996;144(4):363-72.
68. Fujita M, Tase T, Kakugawa Y, Hoshi S, Nishino Y, Nagase S, et al. Smoking, earlier menarche and low parity as independent risk factors for gynecologic cancers in Japanese: a case-control study. *Tohoku J Exp Med*. 2008;216(4):297-307.
69. Jordan SJ, Webb PM, Green AIC. Height, Age at Menarche, and Risk of Epithelial Ovarian Cancer. *Cancer Epidemiology, Biomarkers & Prevention*. 2005;14(8):2045-8.
70. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. *Br J Cancer*. 2001;84(5):714-21.
71. Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F, et al. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. *Int J Cancer*. 1991;49(1):57-60.
72. Lampe B, Kroll N, Piso P, Forner DM, Mallmann P. Prognostic significance of Sugarbaker's peritoneal cancer index for the operability of ovarian carcinoma. *Int J Gynecol Cancer*. 2015;25(1):135-44.
73. Muallem MZ, Sehoul J, Richter R, Babayeva A, Gasimli K, Parashkevova A. Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer. *Int J Gynecol Cancer*. 2020;30(1):62-6.
74. Holschneider CH, Berek JS. Ovarian cancer: Epidemiology, biology, and prognostic factors. *Seminars in Surgical Oncology*. 2000;19(1):3-10.
75. Mousavi AS, Mazhari MM, Guilani MM, Ghaemmaghani F, Behtash N, Akhavan S. Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively? *World J Surg Oncol*. 2010;8:11.
76. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol*. 2002;20(5):1248-59.
77. Bachmann R, Brucker S, Stähler A, Krämer B, Ladurner R, Königsrainer A, et al. Prognostic relevance of high pretreatment CA125 levels in primary serous ovarian cancer. *Mol Clin Oncol*. 2021;14(1):8.

78. Eo W, Kim HB, Lee YJ, Suh DS, Kim KH, Kim H. Preoperative Lymphocyte-Monocyte Ratio Is a Predictor of Suboptimal Cytoreduction in Stage III-IV Epithelial Ovarian Cancer. *J Cancer*. 2016;7(13):1772-9.
79. Amer H, Kartikasari AER, Plebanski M. Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis. *J Pers Med*. 2021;11(12).
80. Rajput M, Kulkarni CV, Yadav A, Sharma S, Dhakad V. The Relationship Between Serum Levels Of CA-125 and Interleukin-6 with the Degree of Differentiation in Ovarian Neoplasms. *Annals of Pathology and Laboratory Medicine*. 2019;6(7).
81. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. *Cancers (Basel)*. 2020;12(12).
82. Kurniadi AL, Hidayat YM, Suardi D, Susanto H, N.A.W G, Prayitno HSH. Peran Serum IL-6 dan CA-125 Prabedah sebagai Prediktor Resektabilitas Tumor pada Kanker Ovarium Tipe Epitel. *Indonesian Journal of Cancer*. 2018;11:151-8.
83. Kampan NC, Xiang SD, McNally OM, Stephens AN, Quinn MA, Plebanski M. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities. *Curr Med Chem*. 2018;25(36):4785-806.
84. Waldner MJ, Foersch S, Neurath MF. Interleukin-6--a key regulator of colorectal cancer development. *Int J Biol Sci*. 2012;8(9):1248-53.
85. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer. *Cancer*. 2007;110(9):1911-28.
86. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. *Gynecol Oncol*. 2014;134(3):455-61.
87. Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? *Tumour Biol*. 2012;33(6):2117-23.
88. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. *Oncogene*. 2002;21(17):2768-73.
89. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. *Gynecol Oncol*. 2009;112(1):40-6.
90. Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. *Gynecol Oncol*. 2010;116(3):301-6.